(Q37995985)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Targeted approaches to the treatment of pulmonary hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

main subject

arterial hypertension

0 references

author

Wassim H. Fares

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Terence K Trow

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

1 reference

21 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic advances in respiratory disease

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

147-159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

PDGF signaling in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Tricuspid annular displacement predicts survival in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Emerging drugs for pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Prostacyclin therapies for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Inflammation, growth factors, and pulmonary vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Endothelin-receptor antagonist treatment of portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Goal-oriented treatment and combination therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Survival in patients with pulmonary arterial hypertension treated with first-line bosentan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Cellular and molecular basis of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Combination therapy in pulmonary arterial hypertension: do we have the right strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Medical treatment of primary pulmonary hypertension: a bridge to transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Early goal-directed therapy in the treatment of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Pulmonary-Hepatic vascular Disorders (PHD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Cyclic GMP phosphodiesterases and regulation of smooth muscle function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Updated clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Pharmacodynamic profile of prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

Stability and antimicrobial effectiveness of treprostinil sodium in Sterile Diluent for Flolan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812441849

21 January 2018

Identifiers

DOI

10.1177/1753465812441849

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22438264%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference